

CORRECTION

Open Access



Correction to: Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension

Mario Boehm¹, Nadine Arnold², Adam Braithwaite², Josephine Pickworth², Changwu Lu¹, Tatyana Novoyatleva¹, David G. Kiely³, Friedrich Grimminger¹, Hossein A. Ghofrani¹, Norbert Weissmann¹, Werner Seeger¹, Allan Lawrie², Ralph T. Schermuly^{1*} and Baktybek Kojonazarov¹

Correction to: BMC Pulmonary Medicine (2018) 18:41
<https://doi.org/10.1186/s12890-018-0604-x>

Following publication of the original article [1], it was brought to the authors' attention that representative histological images in Fig. 3D had been erroneously duplicated from two other articles [2, 3].

The figure has been corrected in the published article and the correct figure is shown in this correction. This correction does not affect the results or conclusion of the article.

The authors apologize for any inconvenience caused.

The original article can be found online at <https://doi.org/10.1186/s12890-018-0604-x>.

*Correspondence: Ralph.Schermuly@innere.med.uni-giessen.de

¹ Universities of Giessen and Marburg Lung Center (UGMLC), Excellence Cluster Cardio-Pulmonary System (ECCPS), Member of the German Center for Lung Research (DZL), Aulweg 130, 35392 Giessen, Germany
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 3 Eplerenone has no direct effect on pressure overload-induced structural RV remodeling. Pharmacological aldosterone antagonism with Eplerenone had no effect on RV total collagen content assessed by picrosirius red stains (percentage of the total RV; **A**), Col1A1 (percentage of sham; **B**) and Col3A1 gene expression (percentage of sham; **C**) Eplerenone did not affect cardiomyocyte hypertrophy (CM diameter, μm ; **D**), ANP (**E**) or BNP gene expression (percentage of sham; **F**). $n = 4\text{--}5$ mice per group; $*p < 0.05$ vs. cntrl

Author details

¹Universities of Giessen and Marburg Lung Center (UGMLC), Excellence Cluster Cardio-Pulmonary System (ECCPS), Member of the German Center for Lung Research (DZL), Aulweg 130, 35392 Giessen, Germany. ²Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. ³Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 20 July 2022

References

- Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, Kiely DG, Grimminger F, Ghofrani HA, Weissmann N, Seeger W, Lawrie A, Schermuly RT, Kojonazarov B. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. *BMC Pulm Med*. 2018;18(1):41. <https://doi.org/10.1186/s12890-018-0604-x>.
- Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, Novoyatleva T, Grimminger F, Hinojosa-Kirschenbaum F, Ghofrani HA, Weissmann N, Seeger W, Liles JT, Schermuly RT. ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2018;197(3):373–85. <https://doi.org/10.1164/rccm.201703-0502OC>.
- Boehm M, Novoyatleva T, Kojonazarov B, Veit F, Weissmann N, Ghofrani HA, Seeger W, Schermuly RT. Nitric oxide synthase 2 induction promotes right ventricular fibrosis. *Am J Respir Cell Mol Biol*. 2019;60(3):346–56. <https://doi.org/10.1165/rccb.2018-0069OC>.